Akebia Therapeutics, Inc.
Securities Investigation
Investors who purchased or acquired AKBA securities are encouraged to come forward.
Investigation opened October 30, 2025
Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Akebia Therapeutics, Inc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Akebia Therapeutics, Inc. (AKBA) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akebia Therapeutics, Inc. (“Akebia” or “the Company”) (NASDAQ: AKBA). Investors who purchased Akebia securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Akebia has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
- 1Whether Akebia Therapeutics, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- 2Whether Akebia Therapeutics, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- 3Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
Key Dates
An investigation is not a lawsuit. If a complaint is filed, a lead plaintiff deadline will be set and posted here.
Why Did AKBA Stock Drop?
On October 28, 2025, Akebia issued a press release “announc[ing] that after meeting with the U.S. Food and Drug Administration (FDA) it has not come to alignment on a path forward for the design of the VALOR clinical trial for the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease (CKD) not on dialysis. As a result, Akebia does not plan to initiate VALOR and therefore does not expect to pursue a broad label for Vafseo for CKD non-dialysis dependent patients.” Following this news, Akebia’s stock price fell $0.99 per share, or 32.04%, to close at $2.10 on October 29, 2025.
How Is Akebia Therapeutics, Inc. (NASDAQ: AKBA) Stock Trading Today?
What Happens After You Contact Us?
Tell us about your purchase
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team reviews your trades at no cost or obligation.
We keep you updated
If a case is filed, we'll contact you about your options and any deadlines.
Submitting information does not create an attorney-client relationship. Our firm works on a contingency fee basis, and you do not need to have sold your shares to contact us.
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Has a lawsuit been filed against Akebia Therapeutics, Inc.?
No complaint has been filed. BG&G is investigating whether investors may have claims. If a securities class action is filed, this page will be updated with the court, class period, and lead plaintiff deadline.
What does a securities investigation mean?
The firm is reviewing public disclosures, stock price movements, and other information to determine whether a company or its officers may have violated the federal securities laws. An investigation does not mean wrongdoing has been established.
Why should I contact the firm now?
Sharing your information early lets us review your transactions and notify you promptly if a case is filed, including any deadline to seek appointment as lead plaintiff.
Does it cost anything?
No. Our firm works on a contingency fee basis, and there is no cost or obligation to contact us.
I sold my AKBA shares. Can I still contact you?
Yes. Potential claims generally depend on when you purchased and whether you suffered a loss, not on whether you still hold the shares.
What documents should I have ready?
Brokerage statements or trade confirmations showing your AKBA purchases, sales, and holdings, including dates, share counts, and prices.